300006 莱美药业
已收盘 02-10 15:00:00
资讯
新帖
简况
莱美药业最新公告：全资子公司湖南康源获得乳酸钠林格注射液药品补充申请批准通知书
证券之星 · 02-06
莱美药业最新公告：全资子公司湖南康源获得乳酸钠林格注射液药品补充申请批准通知书
莱美药业：截至2026年1月30日，公司股东户数为28,650
证券之星 · 02-04
莱美药业：截至2026年1月30日，公司股东户数为28,650
莱美药业（300006）披露控股子公司纳米炭铁混悬注射液联合放疗II期临床试验获伦理批件，1月30日股价上涨1.18%
证券之星 · 01-30
莱美药业（300006）披露控股子公司纳米炭铁混悬注射液联合放疗II期临床试验获伦理批件，1月30日股价上涨1.18%
股市必读：莱美药业（300006）预计2025年全年扣非后净利润亏损1.24亿元至1.39亿元
证券之星 · 01-26
股市必读：莱美药业（300006）预计2025年全年扣非后净利润亏损1.24亿元至1.39亿元
莱美药业（300006）披露2025年度业绩预告，1月23日股价上涨0.19%
证券之星 · 01-23
莱美药业（300006）披露2025年度业绩预告，1月23日股价上涨0.19%
莱美药业(300006)1月20日股东户数3.03万户，较上期减少1.35%
证券之星 · 01-21
莱美药业(300006)1月20日股东户数3.03万户，较上期减少1.35%
股市必读：莱美药业（300006）1月16日董秘有最新回复
证券之星 · 01-19
股市必读：莱美药业（300006）1月16日董秘有最新回复
莱美药业：与AglaeaPharma共建创新研发体系
证券之星 · 01-16
莱美药业：与AglaeaPharma共建创新研发体系
莱美药业：截至2026年1月9日股东户数为30,689
证券之星 · 01-12
莱美药业：截至2026年1月9日股东户数为30,689
股市必读：莱美药业(300006)股东户数2.94万户，较上期减少6.26%
证券之星 · 01-07
股市必读：莱美药业(300006)股东户数2.94万户，较上期减少6.26%
莱美药业（300006）披露控股子公司诉讼事项达成和解，1月5日股价上涨2.53%
证券之星 · 01-05
莱美药业（300006）披露控股子公司诉讼事项达成和解，1月5日股价上涨2.53%
每周股票复盘：莱美药业（300006）制定融资及担保管理制度
证券之星 · 01-03
每周股票复盘：莱美药业（300006）制定融资及担保管理制度
莱美药业：控股子公司暂无铁死亡研究项目
证券之星 · 2025-12-29
莱美药业：控股子公司暂无铁死亡研究项目
莱美药业：截至2025年12月19日股东户数为31,359
证券之星 · 2025-12-23
莱美药业：截至2025年12月19日股东户数为31,359
莱美药业：截至2025年12月10日股东户数为31,490
证券之星 · 2025-12-16
莱美药业：截至2025年12月10日股东户数为31,490
莱美药业：截至2025年12月10日股东户数为31,490户
证券之星 · 2025-12-12
莱美药业：截至2025年12月10日股东户数为31,490户
莱美药业：积极评估AI在新药研发中的应用价值
证券之星 · 2025-12-10
莱美药业：积极评估AI在新药研发中的应用价值
莱美药业(300006.SZ)控股子公司取得两项医疗器械注册证
智通财经 · 2025-12-10
莱美药业(300006.SZ)控股子公司取得两项医疗器械注册证
莱美药业(300006.SZ)控股子公司获得药物临床试验批准通知书
智通财经 · 2025-12-04
莱美药业(300006.SZ)控股子公司获得药物临床试验批准通知书
莱美药业：截至2025年11月28日股东户数为33,303
证券之星 · 2025-12-04
莱美药业：截至2025年11月28日股东户数为33,303
加载更多
公司概况
公司名称：
重庆莱美药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-10-30
主营业务：
重庆莱美药业股份有限公司的主营业务是医药制造。公司的主要产品是抗肿瘤药、消化系统药、肠外营养药、抗感染类。公司产品获得“2021年中国产学研合作创新与促进奖”、获得“2022年福建省科学技术进步一等奖”等多项荣誉称号。
发行价格：
16.50
{"stockData":{"symbol":"300006","market":"SZ","secType":"STK","nameCN":"莱美药业","latestPrice":5.14,"timestamp":1770707001000,"preClose":5.12,"halted":0,"volume":20035038,"delay":0,"changeRate":0.0039,"floatShares":1056000000,"shares":1056000000,"eps":-0.1017,"marketStatus":"已收盘","change":0.02,"latestTime":"02-10 15:00:00","open":5.13,"high":5.19,"low":5.07,"amount":103000000,"amplitude":0.0234,"askPrice":5.15,"askSize":3358,"bidPrice":5.14,"bidSize":1736,"shortable":0,"etf":0,"ttmEps":-0.1017,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.12,"symbolType":"stock","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":5.63,"lowLimit":4.61,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1055911205,"isCdr":false,"pbRate":2.94,"roa":"--","roe":"--","epsLYR":-0.0832,"committee":-0.316605,"marketValue":5427000000,"turnoverRate":0.019,"status":0,"floatMarketCap":5427000000},"requestUrl":"/m/hq/s/300006","defaultTab":"news","newsList":[{"id":"2609595213","title":"莱美药业最新公告：全资子公司湖南康源获得乳酸钠林格注射液药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609595213?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:59","pubTimestamp":1770382771,"startTime":"0","endTime":"0","summary":"莱美药业(300006.SZ)公告称，全资子公司湖南康源收到国家药品监督管理局核准签发的乳酸钠林格注射液（规格：500ml）《药品补充申请批准通知书》，通过仿制药质量和疗效一致性评价，并同意相关变更。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2608873383","title":"莱美药业：截至2026年1月30日，公司股东户数为28,650","url":"https://stock-news.laohu8.com/highlight/detail?id=2608873383","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608873383?lang=zh_cn&edition=full","pubTime":"2026-02-04 09:06","pubTimestamp":1770167178,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘，请问1月31日的股东户数是多少个？莱美药业回复：尊敬的投资者，您好。截至2026年1月30日，公司股东户数为28,650。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400007761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2607041482","title":"莱美药业（300006）披露控股子公司纳米炭铁混悬注射液联合放疗II期临床试验获伦理批件，1月30日股价上涨1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607041482","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607041482?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:35","pubTimestamp":1769783718,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，莱美药业报收于5.15元，较前一交易日上涨1.18%，最新总市值为54.38亿元。近日，重庆莱美药业股份有限公司控股子公司四川瀛瑞医药科技有限公司自主研发的纳米炭铁混悬注射液联合放疗II期临床试验获得四川大学华西医院临床试验伦理审查委员会批件，正式进入II期临床试验阶段。纳米炭铁是以Fe2+为抗癌成分、纳米炭为载体的新一代纳米药物，通过调控铁死亡通路发挥抗肿瘤作用，瘤内注射可抑制肿瘤生长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2606726810","title":"股市必读：莱美药业（300006）预计2025年全年扣非后净利润亏损1.24亿元至1.39亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606726810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606726810?lang=zh_cn&edition=full","pubTime":"2026-01-26 01:09","pubTimestamp":1769360952,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，莱美药业报收于5.29元，上涨0.19%，换手率3.14%，成交量33.17万手，成交额1.75亿元。交易信息汇总资金流向1月23日主力资金净流出3241.51万元；游资资金净流出468.27万元；散户资金净流入3709.78万元。莱美药业发布业绩预告，预计2025年全年归属净利润亏损1.2亿元至1.35亿元。公司公告汇总2025年度业绩预告重庆莱美药业股份有限公司预计2025年度归属于上市公司股东的净利润亏损12,000.00万元至13,500.00万元，上年同期亏损8,780.44万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006"],"gpt_icon":0},{"id":"2605405418","title":"莱美药业（300006）披露2025年度业绩预告，1月23日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605405418","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605405418?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:19","pubTimestamp":1769177966,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，莱美药业报收于5.29元，较前一交易日上涨0.19%，最新总市值为55.86亿元。该股当日开盘5.27元，最高5.36元，最低5.22元，成交额达1.75亿元，换手率为3.14%。近日，重庆莱美药业股份有限公司披露《2025年度业绩预告》。公告显示，公司预计2025年度归属于上市公司股东的净利润亏损12,000.00万元至13,500.00万元，上年同期亏损8,780.44万元；扣除非经常性损益后的净利润亏损12,410.00万元至13,910.00万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300006","BK0070"],"gpt_icon":0},{"id":"2605069177","title":"莱美药业(300006)1月20日股东户数3.03万户，较上期减少1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605069177","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605069177?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:33","pubTimestamp":1768988020,"startTime":"0","endTime":"0","summary":"证券之星消息，近日莱美药业披露，截至2026年1月20日公司股东户数为3.03万户，较1月9日减少414.0户，减幅为1.35%。在化学制药行业个股中，莱美药业股东户数低于行业平均水平，截至1月20日，化学制药行业平均股东户数为3.43万户。从股价来看，2026年1月9日至2026年1月20日，莱美药业区间跌幅为6.99%，在此期间股东户数减少414.0户，减幅为1.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100029104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"gpt_icon":0},{"id":"2604971179","title":"股市必读：莱美药业（300006）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604971179","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604971179?lang=zh_cn&edition=full","pubTime":"2026-01-19 02:13","pubTimestamp":1768759989,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，莱美药业报收于4.9元，下跌2.78%，换手率3.12%，成交量32.91万手，成交额1.62亿元。公司与搭建了多靶点小分子化合物药筛选平台和基于蛋白组学的疾病早期检测和诊断技术开发平台的AglaeaPharma共同投资设立了广西阿格莱雅。公司将持续关注项目后续进展情况并及时履行信息披露义务。当日关注点来自交易信息汇总：1月16日主力资金净流出1775.88万元，显示主力短期内呈离场态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900000794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2603296653","title":"莱美药业：与AglaeaPharma共建创新研发体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2603296653","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603296653?lang=zh_cn&edition=full","pubTime":"2026-01-16 16:42","pubTimestamp":1768552925,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业01月16日在投资者关系平台上答复投资者关心的问题。该公司的业务方向有哪些？公司与搭建了多靶点小分子化合物药筛选平台和基于蛋白组学的疾病早期检测和诊断技术开发平台的AglaeaPharma共同投资设立了广西阿格莱雅。目前，AglaeaPharma项目平台已搭建了多个技术平台、产品管线和系列产品，形成了全球布局的创新研发体系。公司将持续关注项目后续进展情况并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600025952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2602994245","title":"莱美药业：截至2026年1月9日股东户数为30,689","url":"https://stock-news.laohu8.com/highlight/detail?id=2602994245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602994245?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:09","pubTimestamp":1768201752,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘，请问1月10日的股东户数是多少个？莱美药业回复：尊敬的投资者，您好。截至2026年1月9日，公司股东户数为30,689。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200014269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2601812819","title":"股市必读：莱美药业(300006)股东户数2.94万户，较上期减少6.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601812819","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601812819?lang=zh_cn&edition=full","pubTime":"2026-01-07 02:00","pubTimestamp":1767722450,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，莱美药业报收于5.22元，下跌0.95%，换手率2.27%，成交量23.94万手，成交额1.26亿元。股本股东变化股东户数变动截至2025年12月31日，公司股东户数为2.94万户，较12月19日减少1963户，减幅6.26%。耀匀医药已投入的1400万元中，693.18万元归成都金星所有，706.82万元归耀匀医药所有且不再返还。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700000906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2601088725","title":"莱美药业（300006）披露控股子公司诉讼事项达成和解，1月5日股价上涨2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601088725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601088725?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:38","pubTimestamp":1767623899,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，莱美药业报收于5.27元，较前一交易日上涨2.53%，最新总市值为55.65亿元。该股当日开盘5.14元，最高5.38元，最低5.08元，成交额达2.44亿元，换手率为4.44%。近日，莱美药业发布关于控股子公司诉讼事项达成和解的公告。公告显示，公司控股子公司成都金星健康药业有限公司与成都耀匀医药科技有限公司等就增资协议纠纷达成和解，各方已签署补充协议，解除原增资协议。案件目前处于执行阶段，相关方已达成和解。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2600889060","title":"每周股票复盘：莱美药业（300006）制定融资及担保管理制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2600889060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600889060?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:20","pubTimestamp":1767381620,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，莱美药业报收于5.14元，较上周的5.26元下跌2.28%。本周，莱美药业12月29日盘中最高价报5.41元。12月31日盘中最低价报5.12元。莱美药业当前最新总市值54.27亿元，在化学制药板块市值排名93/150，在两市A股市值排名3148/5181。本周关注点公司公告汇总：莱美药业审议通过制定融资管理制度及担保管理办法的议案。其中，绩效考核方案因关联董事回避，表决结果为同意6票，其余两项议案均获全票通过。会议召集程序符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2595884377","title":"莱美药业：控股子公司暂无铁死亡研究项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2595884377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595884377?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:15","pubTimestamp":1766996111,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司如何看待人脑工程？退行性病变这一领域，铁死亡的研究越来越深入了，瀛瑞的研究未来会考虑这一块吗？莱美药业回复：尊敬的投资者，您好。公司控股子公司四川瀛瑞医药科技有限公司暂无上述研究项目。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900017369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2593955467","title":"莱美药业：截至2025年12月19日股东户数为31,359","url":"https://stock-news.laohu8.com/highlight/detail?id=2593955467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593955467?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:42","pubTimestamp":1766475733,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问截至12月20日公司的股东人数是多少？谢谢！莱美药业回复：尊敬的投资者，您好。截至2025年12月19日，公司股东户数为31,359。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300019587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2591774606","title":"莱美药业：截至2025年12月10日股东户数为31,490","url":"https://stock-news.laohu8.com/highlight/detail?id=2591774606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591774606?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:09","pubTimestamp":1765868956,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：截止12月9日，公司最新的股东户数是多少？莱美药业回复：尊敬的投资者，您好。截至2025年12月10日，公司股东户数为31,490。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600019572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2590736915","title":"莱美药业：截至2025年12月10日股东户数为31,490户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590736915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590736915?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:03","pubTimestamp":1765522996,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)12月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止 2025 年 12 月 10 日股东人数是多少？谢谢！莱美药业回复：答：尊敬的投资者您好。截至2025 年12 月10日，公司股东户数为31,490户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200018124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2590582793","title":"莱美药业：积极评估AI在新药研发中的应用价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2590582793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590582793?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:53","pubTimestamp":1765371183,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在药物筛选和临床上会使用或者引进AI智能化的辅助工具吗莱美药业回复：尊敬的投资者，您好！公司持续关注人工智能领域的前沿发展，积极评估其在新药研发、数据分析、流程优化等生产经营管理场景中的应用价值。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000038003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2590530416","title":"莱美药业(300006.SZ)控股子公司取得两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2590530416","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590530416?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:11","pubTimestamp":1765354272,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)公告，公司控股子公司海南莱美医疗器械有限公司(简称“莱美医疗器械”)收到海南省药品监督管理局颁发的两项《医疗器械注册证》，产品名称为：医用电子内窥镜图像处理器、电子支气管镜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300006","BK1574","09997","BK0239","BK1222","BK0070","BK1100","09996","BK1583","159883"],"gpt_icon":0},{"id":"2588001187","title":"莱美药业(300006.SZ)控股子公司获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2588001187","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588001187?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:03","pubTimestamp":1764835400,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布公告，近日，公司控股子公司四川瀛瑞医药科技有限公司(简称“瀛瑞医药”)自主研发的创新抗癌药物“纳米炭铁混悬注射液”(简称“纳米炭铁”)获国家药品监督管理局签发《药物临床试验批准通知书》，同意纳米炭铁联合标准放疗在实体瘤患者中开展临床试验。本次获批的临床试验将进一步验证“纳米炭铁+放疗”联合方案的安全性和潜在疗效，陆续在多个临床中心启动“纳米炭铁+放疗”研究，重点关注局部治疗难度较大的实体瘤，以期在确保安全性的前提下，进一步探索联合疗法的临床价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"莱美药业(300006.SZ)控股子公司获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300006","BK0070","BK0239"],"gpt_icon":0},{"id":"2588009564","title":"莱美药业：截至2025年11月28日股东户数为33,303","url":"https://stock-news.laohu8.com/highlight/detail?id=2588009564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588009564?lang=zh_cn&edition=full","pubTime":"2025-12-04 15:36","pubTimestamp":1764833785,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业(300006)12月04日在投资者关系平台上答复投资者关心的问题。投资者提问：截止2025年11月28日，公司最新股东户数？莱美药业回复：尊敬的投资者，您好。截至2025年11月28日，公司股东户数为33,303。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400018515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770717823765,"stockEarnings":[{"period":"1week","weight":0.0302},{"period":"1month","weight":-0.0321},{"period":"3month","weight":-0.0192},{"period":"6month","weight":0.0039},{"period":"1year","weight":0.369},{"period":"ytd","weight":-0.0039}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆莱美药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"28650人(较上一季度减少5.37%)","perCapita":"36852股","listingDate":"2009-10-30","address":"重庆市南岸区玉马路99号","registeredCapital":"105591万元","survey":" 重庆莱美药业股份有限公司的主营业务是医药制造。公司的主要产品是抗肿瘤药、消化系统药、肠外营养药、抗感染类。公司产品获得“2021年中国产学研合作创新与促进奖”、获得“2022年福建省科学技术进步一等奖”等多项荣誉称号。","listedPrice":16.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱美药业,300006,莱美药业股票,莱美药业股票老虎,莱美药业股票老虎国际,莱美药业行情,莱美药业股票行情,莱美药业股价,莱美药业股市,莱美药业股票价格,莱美药业股票交易,莱美药业股票购买,莱美药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}